May 12, 2022 8:04am EDT Sapience Therapeutics Announces Poster Presentation on ST101 Phase 1 Study Results at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022
May 03, 2022 8:00am EDT Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma
Apr 11, 2022 10:00am EDT Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways
Mar 31, 2022 8:00am EDT Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs
Mar 15, 2022 4:05pm EDT Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect
Mar 09, 2022 8:00am EST Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
Feb 15, 2022 8:00am EST Sapience Therapeutics Strengthens Executive Team with Appointments of Marisa Frackman as Chief Financial Officer and Seth I. Rubin as General Counsel
Feb 03, 2022 4:05pm EST Sapience Therapeutics to Present at Guggenheim Healthcare Talks, 2022 Oncology Conference
Jan 06, 2022 8:00am EST Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101
Dec 15, 2021 8:16am EST Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma
